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planning speciﬁc interventions and for evaluating patterns of
pharmaceutical and hospital use.
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OBJECTIVES: In Ukraine forms insurance medicine and for-
mulary system. Annually state selects more than 3% from a gross
national product. The limited tool on pharmaceuticals is insuf-
ﬁciently. METHODS: We in the commission of Health Ministry
of Ukraine have developed regulations about the National list of
the essential medicines with use the pharmacoeconomic analysis
for carrying out of the state purchases. The analysis “cost-
minimization” dominates, the analysis “cost-effectiveness” will
carry out seldom in connection with complexity of searching of
the data about effectiveness of drugs. We have developed tech-
niques the pharmacoeconomic analysis for creation of the 
formulary. RESULTS: We have created «The Program of phar-
macoeconomical evaluation of drugs in Ukraine», which
includes the education of the pharmacists on pharmacoeconom-
ics and organization of pharmacoeconomical researches. We
have developed recommendations on the pharmacoeconomic
analysis for carrying out in Ukraine in view of its economic,
demographic features. At the present stage in Ukraine the State
formulary of medicines is developed. The government is hesitant
to apply pharmacoeconomics widely in pricing and reimburse-
ment. There is a system of gathering of pharmacoepidemiologi-
cal data. Little experience exists in quality of life, measurement
and cost-utility techniques. On the basis of materials of ISPOR
we prepare the textbook “Pharmacoeconomics” by Ukrainian.
More than 4000 practical pharmacists are acquainted with phar-
macoeconomical analysis. The original educational program on
pharmacoeconomics for the clinical pharmacists is created.
CONCLUSIONS: The pharmacoeconomics is necessary for cre-
ation of the insurance medicine and State Formulary in Ukraine.
The education of the doctors and pharmacists on pharmacoeco-
nomics is necessary for improving quality spent researches. Cre-
ation of the state formulary of medicines after results the
pharmacoeconomical analysis will allow to improve medicinal
provision of the population of Ukraine.
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OBJECTIVES: To evaluate the effects of Medical Savings
Accounts (MSAs), a health care ﬁnancing method, on the health
care utilization and health expenditure of the insured employees
in China. METHODS: The study used a before and after design.
A multivariate econometric model was used to analyse the effects
of MSAs reform on the changes in health care utilization and
health expenditure, while controlling the effects of all other con-
founding factors. The use of health care and health expenditure
was modeled in a two-step process: whether or not to seek health
care; and how much to use health care and the resulting expen-
diture, giving that health care was to be used. The data are from
a series of annual surveys at the individual level conducted in a
Chinese city during 1993 to 1999. RESULTS: The use of MSAs
in the Chinese city is associated with the shift of health care 
utilization from inpatient and emergency settings to outpatient
settings. It is also associated with reduced use of high-tech diag-
nostic services. But overall health care utilization level and health
expenditure continued to increase after the MSAs reform. CON-
CLUSIONS: The use of MSAs in the Chinese city resulted in the
reduction of inpatient care and emergency care but failed to
reduce the overall health care utilization and health expenditure
per insured patient. The results suggest that MSAs may have
more income effects than substitution effects on health care 
utilization and expenditure.
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OBJECTIVES: To highlight the importance of considering both
age and gender of users (population (pop) with any prescription)
if analyzing pharmaceutical expenditure. METHODS: All
primary health care prescriptions (2003) have been considered
(95 million prescriptions; 4.2 million users; 1237 million €). Indi-
cators analyzed: prescriptions per user (P/U), cost per prescrip-
tion (C/P) and cost per user (C/U), all from administration
viewpoint. Risk of consuming (U/Pop) has been also calculated
according to age and gender. RESULTS: Global: C/U: €291.9;
P/U: 22.4; C/P: €13.0. Men present prescriptions more expensive
(+€1.5), but women are more expensive (€305.6 vs. €275.4)
because on average they demand 4.8 prescriptions more than
men P/U grows exponentially (R2 = 0.929) until 89 y.o.(63.4).
Min: 4.3(10 y.o.). C/P varies considerably until 28 y.o. (avg:
€10.0; Pearson v.c:32.1). Prescriptions of growth hormone
increase the C/P a 83% among 12–16 y.o. Since 29 y.o. C/P sta-
bilizes (avg: €12.9; Pearson v.c.:8.6) presenting an upward trend
at ages close to retirement age (chronic illnesses and copayment).
C/U behaves exponentially until 88 y.o. (R2 = 0.962). At 88 y.o.
C/U is 3 times higher than global average and 28.5 higher than
at 5 y.o. Since 17 y.o., women consume more medicines than
men, but men present prescriptions more expensive than women
so there are alternations in C/U. U/Pop at 70 y.o. is 1.84 times
higher than at 30 y.o.(prob.0.90 vs. 0.49), and the difference in
C/U is €569. For equal ages, there are also differences in U/Pop
between primary health care teams (PHCTs) because of, for
example, other socio-economic and geographical variables.
CONCLUSIONS: It’s important to include age and gender of
users in comparative analysis between PHCTs in order to con-
sider differences in the population pyramid and in utilization
levels. Benchmarking activity between PHCTs is being carried
out monthly with these three standardized indicators. These
reports allow to locate inefﬁciency with more accuracy and to
apply measures more effective.
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